Partnerships and co-selling for enterprise revenue teams for healthcare and life sciences in the DACH region

This edition of the Growth Broker playbook is written for commercial leaders at healthtech, medtech, and life-sciences companies operating in the DACH region. In this market, DACH buyers reward rigour, documentation, and long-cycle trust — not urgency-led campaigns, so the way you install partnerships and co-selling has to be shaped to that reality from day one.

Enterprise partnerships and co-selling is not a bigger version of the startup playbook. It is using another company's distribution to reach buyers you cannot cost-effectively reach yourself, run under governance, procurement, and regional constraints most founders never encounter.

The value of partnerships and co-selling at enterprise scale is compounded by distribution: one great partner is worth ten marketing hires, and applied across dozens of teams the delta becomes a full quarter of pipeline.

The right shape at enterprise is a hub-and-spoke: a central team owns the model, the metric, and the tooling; regional teams own execution against local ICP nuance. Fully centralised deployments miss context; fully federated deployments diverge inside a quarter.

Inside healthcare and life sciences, the binding constraint is almost always regulated-sale cycle length, not intent, and in the DACH region it is compounded by the fact that trust-building cycle length, not intent is what actually gates growth. Partnerships and co-selling is only useful here when it is pointed at both constraints at once.

Instrument sourced and influenced pipeline from partners as a shared metric across BUs before you argue about incentives. Anything less turns the operating review into a data debate instead of a revenue conversation.

The enterprise-specific failure mode is signing MOUs no one operationalises, magnified by the fact that governance rewards process compliance over outcome. Design controls that catch the trap without slowing the model.

Rollout takes two quarters, not two months. Pilot with one BU that already has strong ops. Publish a scorecard. Then expand — never in parallel across five regions at once.

Enterprise partnerships and co-selling done right is the difference between a decade of predictable growth and a decade of restructures. Done wrong, it becomes another initiative buried under next year's slide.

Concretely for healthcare and life sciences in the DACH region: the healthcare teams that install this get past procurement instead of dying in it, and one properly-run DACH account survives leadership changes and compounds for years. That is the reason it is worth installing partnerships and co-selling deliberately for this market rather than importing a playbook designed for somewhere else.